Compare INTG & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTG | RLYB |
|---|---|---|
| Founded | 1965 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.0M | 86.6M |
| IPO Year | 1995 | 2021 |
| Metric | INTG | RLYB |
|---|---|---|
| Price | $35.17 | $16.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 111.2K | 25.5K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.67 | ★ 6.16 |
| Revenue | ★ $74,753,000.00 | $858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $52.49 | ★ $2.75 |
| Revenue Growth | 4.43 | ★ 43.00 |
| 52 Week Low | $12.25 | $0.48 |
| 52 Week High | $52.00 | $17.57 |
| Indicator | INTG | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 53.81 | 63.58 |
| Support Level | $31.59 | $15.68 |
| Resistance Level | $38.27 | $17.09 |
| Average True Range (ATR) | 2.89 | 0.42 |
| MACD | 0.85 | 0.05 |
| Stochastic Oscillator | 81.77 | 66.67 |
The Intergroup Corp is a company operating in the real estate sector. It was formed to buy, develop, operate, rehabilitate, and dispose of real property of various types and descriptions, as well as to engage in other related business and investment activities. The company operates through three segments: Hotel, Real Estate, and Investment Transactions. The Hotel Operations segment, which generates the majority of the revenue, covers the operation of the Hilton hotel and garage. The Real Estate Operations segment involves the management of multifamily rental properties, while the Investment Transactions segment includes investments of cash in marketable securities and other assets.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.